Lifetime Overdiagnosis for NSCLC (excluding BAC) with LDCT Screening at Approximately 3%
| Ps1a% (95% CI) | ||||||
| NSCLC Excluding BAC | BAC | All NSCLC | ||||
Scenario |
vs No Screening | vs CXR | vs No Screening | vs CXR | vs No Screening | vs CXR |
| 3 Annual Screens | ||||||
With 7 y follow-up |
21 (16-25) |
9 (6-12) |
85 (69-93) |
71 (52-83) |
31 (27-34) |
19 (16-23) |
With Lifetime follow-up |
2.6 (2.0-3.3) |
1.2 (0.7-1.7) |
49 (34-71) |
41 (28-62) |
11 (7-15) |
9 (5-13) |
| 5 Annual Screens | ||||||
With 5 y follow-up |
45 (39-49) |
16 (12-21) |
91 (84-95) |
73 (56-85) |
53 (48-56) |
25 (21-29) |
With Lifetime follow-up |
3.2 (2.6-3.8) |
1.3 (0.8-1.9) |
51 (33-71) |
42 (27-60) |
12 (7-15) |
9 (5-13) |
Abbreviations: BAC, bronchioloalveolar cell carcinoma; CXR, chest radiography; or no screening cohort divided by total number of screen-detected cancers LDCT, low-dose computed tomography; NSCLC, non-small cell lung cancer. In LDCT cohort. aOverdiagnosis rate is total cancers in LDCT cohort minus total cancers in CXR
Patz E.F, Jr, Pinksy P. Gatsonis C. et al. Overdiagnosis in Low-Dose Computed Tomography Screening for Lung Cancer. JAMA
Intern Med. 2014:174(2):269-274 dol: 10.1001/jamainternmed.2013.12738